Auriga Reiterates a 'Buy' on MedAssets (MDAS); Tweaking Model While We Find Current Price Compelling
Tweet
Share
E-mailGet Alerts MDAS Hot Sheet
Price: $31.35 --0%
Rating Summary:
3 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
3 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Auriga reiterates a 'Buy' on MedAssets (NASDAQ: MDAS), PT lowered by $1 to $21.
Auriga analyst says, "We had overstated G&A expense and stock-based compensation relative to guidance while understating the amount of acquisition-related expenses, leading to a modest reduction to GAAP and adjusted cash EPS. Importantly, despite the slight haircut to projections and our target, we find MDAS to be a compelling buy at current levels, with nearly 40% upside to our target. Heads-down execution is the rule of the day, given the shellacking that earnings and guidance took last month. It's baby steps for now, while the next catalyst ahead of Q1 earnings could be analyst commentary during its annual Health Business Summit on April 28."
"...The net impact is a penny reduction to current year estimates to $0.99, and a $0.04 haircut to FY12 estimates, to $1.16, on less than $1 million reduction in revenue (from revenue cycle management -- RCM)."
For more ratings news on MedAssets click here and for the rating history of MedAssets click here.
Shares of MedAssets closed at $14.88 yesterday.
Auriga analyst says, "We had overstated G&A expense and stock-based compensation relative to guidance while understating the amount of acquisition-related expenses, leading to a modest reduction to GAAP and adjusted cash EPS. Importantly, despite the slight haircut to projections and our target, we find MDAS to be a compelling buy at current levels, with nearly 40% upside to our target. Heads-down execution is the rule of the day, given the shellacking that earnings and guidance took last month. It's baby steps for now, while the next catalyst ahead of Q1 earnings could be analyst commentary during its annual Health Business Summit on April 28."
"...The net impact is a penny reduction to current year estimates to $0.99, and a $0.04 haircut to FY12 estimates, to $1.16, on less than $1 million reduction in revenue (from revenue cycle management -- RCM)."
For more ratings news on MedAssets click here and for the rating history of MedAssets click here.
Shares of MedAssets closed at $14.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TechnipFMC (FTI) PT Raised to $30 at BTIG
- Equinor ASA (EQNR) Tops Q1 EPS by 22c, misses on revenue
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Auriga, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
